Kite entered into its first CRADA in 2012, with Dr. In exchange for quarterly cash payments, the NCI conducts clinical trials and laboratory work on many of its own patented technologies, with the understanding that Kite will have the rights to commercialize any successful products developed through the CRADA. | Partnership for Public Service / Aaron ClamageĪccording to Kite’s filings with the Securities and Exchange Commission (SEC), Kite has secured three Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI). Arie Belldegrun, and is also listed as a “Special Advisor” to Kite on their website. Rosenberg mentored Kite CEO and co-Founder Dr. Rosenberg is the Principal Investigator for the National Cancer Institute on Kite’s 2012 CRADA. (The NIH has a concise description for non-scientists here.)ĭr. T-cell receptor therapy is the latest breakthrough in cancer treatment, and involves modifying a patient’s own cells to better track and destroy cancer proteins, and then reintroducing them into the body. residents.įor a selected bibliography of news stories on Kite’s relationship with the National Cancer Institute, see here: Kite Pharma, Inc., which is racing Juno Therapeutics and Swiss pharmaceutical giant Novartis to successfully bring the first T-cell receptor (TCR) therapy to market, relies heavily on government support in the course of its research and development.Īs noted previously by KEI, in various comments to the National Institutes of Health, the NIH rarely discloses detailed information on its connections with industry, raising concerns about how the NIH licenses out taxpayer-funded technologies without regard for future prices or access for U.S. Other KEI comments on NIH licenses are found here.) (More on government funded inventions here.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |